Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas

被引:26
作者
Le Hir, H
Charlet-Berguerand, N
Gimenez-Roqueplo, AP
Mannelli, M
Plouin, PF
de Franciscis, V
Thermes, C [1 ]
机构
[1] Univ Paris 06, CNRS, Ctr Genet Mol, Lab Associe, F-91198 Gif Sur Yvette, France
[2] CNR G Salvatore, Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Naples, Italy
[3] Hop Broussais, Mol Genet Lab, F-75674 Paris, France
[4] Hop Broussais, Serv Hypertens Arterielle, F-75674 Paris, France
[5] Univ Florence, Dept Clin Pathophysiol, I-50121 Florence, Italy
关键词
cancer; pheochromocytoma; RET; splicing; RNA; adrenal medulla;
D O I
10.1159/000012118
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activating mutations of the RET oncogene cause the inheritance of multiple endocrine neoplasia type 2 (MEN2). The RET pre-mRNA is spliced into several transcripts coding for multiple isoforms, including Ret9 and Ret51. When harboring activating mutations in the cytoplasmic region, the Ret51 protein displays a higher in vitro transforming efficiency as compared to the corresponding Ret9 isoform. We investigated whether a more transforming isoform was preferentially expressed in MEN2 tumors as compared to normal tissues or sporadic pheochromocytomas. By quantitative RNases protection assays, we measured the absolute abundance of the 3' splice variants in pheochromocytomas and in normal tissues. The proportion of RET51 transcripts was highly dispersed between tumors and normal tissues. In familiar tumors the proportion of RET51 transcripts was significantly larger (48.1%) than in sporadic tumors (36.75%). This result suggests that the preferential expression of the Ret51 protein isoform, even though moderate, is a growth advantage for MEN2 tumors. Copyright(C)2000S.KargerAG,Basel.
引用
收藏
页码:311 / 318
页数:8
相关论文
共 40 条
[1]   Grb2 binding to the different isoforms of Ret tyrosine kinase [J].
Alberti, L ;
Borrello, MG ;
Ghizzoni, S ;
Torriti, F ;
Rizzetti, MG ;
Pierotti, M .
ONCOGENE, 1998, 17 (09) :1079-1087
[2]   Identification of Shc docking site on Ret tyrosine kinase [J].
Arighi, E ;
Alberti, L ;
Torriti, F ;
Ghizzoni, S ;
Rizzetti, MG ;
Pelicci, G ;
Pasini, B ;
Bongarzone, I ;
Piutti, C ;
Pierotti, MA ;
Borrello, MG .
ONCOGENE, 1997, 14 (07) :773-782
[3]   A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins [J].
Asai, N ;
Murakami, H ;
Iwashita, T ;
Takahashi, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (30) :17644-17649
[4]  
ASAI N, 1995, MOL CELL BIOL, V15, P1613
[5]  
AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305
[6]   TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret [J].
Baloh, RH ;
Tansey, MG ;
Golden, JP ;
Creedon, DJ ;
Heuckeroth, RO ;
Keck, CL ;
Zimonjic, DB ;
Popescu, NC ;
Johnson, EM ;
Milbrandt, J .
NEURON, 1997, 18 (05) :793-802
[7]   Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex [J].
Baloh, RH ;
Tansey, MG ;
Lampe, PA ;
Fahrner, TJ ;
Enomoto, H ;
Simburger, KS ;
Leitner, ML ;
Araki, T ;
Johnson, EM ;
Milbrandt, J .
NEURON, 1998, 21 (06) :1291-1302
[8]  
BORRELLO MG, 1994, ONCOGENE, V9, P1661
[9]   Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase [J].
BujBello, A ;
Adu, J ;
Pinon, LGP ;
Horton, A ;
Thompson, J ;
Rosenthal, A ;
Chinchetru, M ;
Buchman, VL ;
Davies, AM .
NATURE, 1997, 387 (6634) :721-724
[10]  
CALIFANO D, 1995, ONCOGENE, V11, P107